http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110655581-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2019-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110655581-B |
| titleOfInvention | Anti-carcinoembryonic antigen antibody and preparation method and application thereof |
| abstract | The invention provides an anti-CEA antibody, which comprises a heavy chain variable region and a light chain variable region, wherein the complementarity determining region of the heavy chain variable region comprises CDR-H1 with an amino acid sequence shown as SEQ ID No.1, CDR-H2 with an amino acid sequence shown as SEQ ID No.2 and CDR-H3 with an amino acid sequence shown as SEQ ID No.3, and the complementarity determining region of the light chain variable region comprises CDR-L1 with an amino acid sequence shown as SEQ ID No.4, CDR-L2 with an amino acid sequence shown as SEQ ID No.5 and CDR-L3 with an amino acid sequence shown as SEQ ID No. 6. The inventor utilizes phage display technology to screen CEA scFv, thereby obtaining the high-affinity anti-CEA single-chain antibody. And the CEA-resistant chimeric antigen receptor gene is introduced into T cells by a genetic engineering method to prepare CEA CAR-T, so that the CEA CAR-T cells specifically recognize and kill the CEA-expressing digestive tract tumor cells, thereby realizing the anti-tumor effect of the CEA CAR-T cells. |
| priorityDate | 2019-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 327.